DAFTAR PUSTAKA

1. Cook GK, Gomez K. Molecular basis of hemophilia A. Textbook of Hemophilia Third Edition. Editor: Lee C, Berntorp E, Hoots W. USA. 2014:23-32.
2. Hillman RS, Ault KA, Leporrier M, Rinder HM. Hemophilia and other intrinsic pathway defects. Hematology in Clinical Practice 5th Edition. 2011;33:398-410.
3. Gatot, D. Hemofilia: Tantangan dan Permasalahan di Indonesia. Proceeding Book Seminar Hemofilia. Editor: Garna H, Reniarti L. 2014;1-4.
4. Rotty L. Hemofilia A dan B. Dalam Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi VI. Editor: Setiati S, Alwi I, Sudoyo A, Simadibrata M, Setiyohadi B, Syam AF. Interna Publishing. Jakarta 2014; 2742-2749.
5. Godara H, Hirbe A, Nassif M, Otepka H, Rosenstock A. Inherited Bleeding Disorders. The Washington Manual of Medical Therapeutics 34th Edition, International Edition. 2014; 736-741.
6. Wahid I. Management of Congenital Bleeding Disorders: Focused on Haemophilia. Proceeding Book PIB XV IPD. 2015;48-54.
7. Baker JR, Riske B, Drake JH, Forsberg AD, Atwood R, Voutsis M, *et al*. US Hemophilia Treatment Center population trends 1990-2010: patient diagnoses, demographics, health services utilization. *Haemophilia*. 2013:19;21-26.

8. Astermarkk J. Genetic and environmental risk factors for factor VIII inhibitor development. Textbook of Hemophilia Third Edition. Editor: Lee C, Berntorp E, Hoots W. USA. 2014.
9. Windiastuti E. Hemofilia: Etiologi, Komplikasi, dan Tatalaksana Terkini. Proceeding Book Seminar Hemofilia. Editor: Garna H, Reniarti L. 2014;17-23.
10. DiMichele DM. Inhibitors in Hemophilia: A Primer Fourth Edition. *WFH*. 2008.
11. Wahid I. Update management of haemophilia patient. Update management in Haematology and Medical Oncology Patient, PERHOMPEDIN III. 2015;51-56.
12. Keeling D, Lee C. Immunological Aspects of Inhibitor Development in Haemophilia. *Europ Hematol*. 2008;28-33.
13. Bluml S, McKeever K, Ettinger R, Smolen J, Herbst R. B-cell targeted therapeutics in clinical development. *Arthritis Res Ther*. 2013.
14. Baratawidjaja GK, Rengganis I. Sel-sel Sistem Imun Spesifik. Dalam Buku Ajar Imunologi Dasar Edisi Ke-8. Balai Penerbit FKUI. Jakarta, 2009:93-148.
15. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. *J Immunol*. 2014;193:580-586.
16. Tobon GJ, Izquierdo JH, Canas CA. B Lymphocytes: Development, Tolerance, and Their Role in Autoimmunity – Focus on Systemic Lupus Erythematosus. *Autoimmune Disease*. 2013.

17. Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. *Arthritis Res Ther.* 2013.
18. Silveira AC, Santana MA, Riberio IG, Chaves DG, Filho OA. The IL-10 polarized cytokine pattern in innate and adaptive immunity cells contribute to the development of FVIII inhibitors. *BMC Hematol*. 2015;15.
19. Ugrasena ID. Diagnosis dan Tatalaksana Penyandang Hemofilia Dengan Inhibitor. Proceeding Book Seminar Hemofilia. Editor: Garna H, Reniarti L. 2014;76-87.
20. Makris M, Hay C, Gringer A, D'Oiron. How I treat inhibitors in haemophilia. *Haemophilia*. 2012:18;48-53.
21. Astermark J. FVIII inhibitors: pathogenesis and avoidance. *Blood*. 2015;2045-2051.
22. Canadian Hemophilia Society. All About Inhibitors. 2014.
23. Srivastava A, Brewer AK, Bunschoten EP, Key NS, Kitchen S, Lilinas A, *et al.* Guidelines for the management of hemophilia. *Haemophilia*. 2013:19;c1-c47.
24. Rocha P, Carvalho M, Lopes M, Araujo F. Cost and utilization of treatment in patient with hemophilia. *BMC Health Services Research*. 2015:15;484.
25. Dalton DR. Hemophilia in the Managed Care Setting. *Am J Manag Care*. 2015:21;123-130.

26. Leissinger C, Josephson CD, Granger S, Konkle BA, Jarres RK, Ragni MV, *et al.* Rituximab for treatment of inhibitors in haemophilia A. *Thromb Haemost*. 2014;112:445-458.
27. Liu CL, Ye P, Lin J, Butts CL, Miao CH. Anti-CD20 as the B cell targeting agent in a combined therapy to modulate anti-factor VIII immune responses in hemophilia A inhibitor mice. *Frontiers Immunol*. 2013.
28. Arena GD, Grandone E, Minno MN, Musto P, Minno GD. Acquired Hemophilia A Succesfully Treated with Rituximab. *Mediterr J Hematol Infect Dis*. 2015.
29. Lee C. Historical introduction. Textbook of Hemophilia Third Edition. Editor: Lee C, Berntorp E, Hoots W. USA. 2014.
30. Haemophilia Foundation Australia. Haemophilia. 2013.
31. Gatot, D. Hemofilia: Tantangan dan Permasalahan di Indonesia. Proceeding Book Seminar Hemofilia. Editor: Garna H, Reniarti L. 2014;1-4.
32. Setianingsih I. Dasar Molekul Hemofilia A. Proceeding Book Seminar Hemofilia. Editor: Garna H, Reniarti L. 2014;64-66.
33. Geffen MV, Dardikh M, Verbruggen B. Factor VIII Inhibitor Assays: Methodology, Shortcomings, and Challenges. *J Coagul Dis*. 2009.
34. Afriant R. Diagnostic approach of bleeding disorders: Focused on hemophilia. Update management in Haematology and Medical Oncology Patient, PERHOMPEDIN III. 2015;41-50.
35. Hoffbrand A, Moss PA. Trombosit, koagulasi darah, dan hemostasis. Dalam Kapita Selekta Hematologi Edisi 6. Jakarta : EGC, 2013;293-306.

36. Jarres RK, Singleton T, Leissinger C. Identification and Basic Management of Bleeding Disorders in Adults. JABFM. 2014;27:549-564.
37. Belliveau D, Flanders A, Harvey M, Hawes SA, Mayes C, Payne L, *et al*. Mild hemophilia. Canadian Hemophilia Society. 2007.
38. National Blood Authority. Australian Bleeding Disorders Registry Annual Report 2012-2013. 2013.
39. Mumford AD, Ackroyd S, Aikhan R, Bowles L, Chowdary P, Grainger J, *et al*. Guideline for the diagnosis and management of the rare coagulation disorders. *British J of Haematol*. 2014.
40. Makris M, Kasper C. The World Federation of Hemophilia guidelines on management of haemophilia. *Haemophilia*. 2013:19;1.
41. World Federation of Hemophilia. Guidelines for the Management of Hemophilia 2nd edition. 2012.
42. Liras A, Segovia C, Gaban A. Advanced therapies for the treatment of hemophilia: future perspectives. *Orph J Rare Disease*. 2012:7:97.
43. Owaidah TM. Hemophilia Inhibitors Prevalence, Causes and Diagnosis. Hemophilia. Editor: Batorova A. InTech. 2012:5;67-78.
44. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. *Ther Adv Hematol*. 2013:4;59-72.
45. Tantawy AA. Molecular genetics of hemophilia A: Clinical perspectives. *The Egyptian J*. 2010;11:105-114.
46. Alencar JB, Macedo LC, Barros MF, Rodrigues C, Cadide RC, Sell AM, *et al*. Importance of immune response genes in hemophilia A. *Rev Bras Hematol Hemoter*. 2013;35:280-286.

47. Tunstall O, Astermark J. Strategies for reducing inhibitor formation in severe haemophilia. *Europ J Haematol*. 2015:77;45-50.

48. Mannuci PM. Autoimmune haemophilia. *Blood Transfus*. 2008:6;6-7.

49. Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM. Validation of Nijmegen-Bethesda Assay Modifications to Allow Inhibitor Measurement during Replacement Therapy and Facilitate Inihibitor Surveilance. *J Thromb Haemost*. 2012:10;1055-1061.

50. Franchini M, Lippi G. Acquired factor VIII inhibitors. *Blood*. 2008;112:250-255.

51. Verbruggen B. Diagnosis and quantification of factor VIII inhibitors. *Haemophilia*. 2010:16;20-24.

52. Negrier C. Inhibitors to factor VIII: treatment of acute bleeds. Textbook of Hemophilia Third Edition. Editor: Lee C, Berntorp E, Hoots W. USA. 2014.

53. Association of Hemophilia Clinic Directors of Canada. A Guide to the Management of Patients with Inhibitors to Factor VIII and Factor IX. *AHCDC*. 2010.

54. Callaghan MU, Fogarty PF. What is the Evidence for the Use of Immunomodulatory Agents to Eradicate Inhibitory Antibodies in Patients with Severe Hemophilia A Who Have Previously Failed to Respond to Immune Tolerance Induction? *Hematol*. 2011;405-406.

55. Australian Haemophilia Centre Directors' Organisation. Guidelines for the Treatment of Inhibitors in Haemophilia A and Haemophilia B. 2010.

56. Bianco RP, Neme D, Candela M, Pinto MT. Secondary Prophylaxis with rFVIIa in Hemophilia and Inhibitors: Recommendations from an Experts Committee from Argentina. *Medicina*. 2010:70;209-214.
57. Zhang AH, Skupsky J, Scott DW. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice. *Blood*. 2011;2223-2226.
58. Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, *et al.* Rituximab efficiency deplets increased CD20 expresing T cells in multiple sclerosis patients. *J Immunol*. 2014:193;580-586.
59. Framchini M. Rituximab in the treatment of adult acquired hemophilia A: A systematic review. *Clin Rev Oncol Hematol*. 2007;47-52.
60. Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in hemophilia. *Blood Hematol*. 2014:124;3365-3371.
61. Collins PW, Mathias M, Hanley J, Keeling D, Keenan R, Laffan M. Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. *J Thromb Haemos*. 2009:7;787-794.
62. Lim MY, Nielsen B, Lee K, Kasthuri RS, Key NS, Ma AD. Rituximab as first-line treatment for the management of adult patients with non-severe hemophilia A and inhibitors. *J Thromb Haemos*. 2014:12;897-901.
63. Actor AM, Holley CK, Smith KC. Role of B Cells in Breaking and Maintaining Tolerance to Clotting Factor VIII in Congenital and Acquired Hemophilia A. *Antibodies*. 2014;3:192-204.

64. Noone D, O'Mahony B, Van JP, Prihodova L. A Survey of the outcome of prophylaxis, on-demand treatment, or combined treatment in 18-35 yo men with severe hemophilia in six countries. *Haemophilia*. 2013;19:44-50.
65. Carcao M, Louis J, Poon M, Grunebaum E, Lacroix S, Stain AM, *et al*. Rituximab for congenital haemophilias with inhibitors: a Canadian experience. *Haemophilia*. 2006;12:7-18
66. Sujarweni VW. Pengujian normalitas dan linieritas dalam Buku SPSS Untuk Penelitian. Penerbit: Pustaka Baru Press, Yogyakarta. 2015:4:52-56.